Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

The Lancet Oncology · Published 2026-07-27 · DOI 10.1016/s1470-2045(26)00194-4

Authors (12)

Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi, Edward M Uchio, Seung Il Jung, Trinity J Bivalacqua, Gary D Steinberg, Neal D Shore, James M Burke, Hiroshi Kitamura, Ben Tran, Roger Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tyson, M., Nam, J., Joshi, S., et al. (2026). Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00194-4

Related articles

• Cretostimogene grenadenorepvec: promise beyond response · The Lancet Oncology · 2026 · Cites or is cited by this article · Same journal
• Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research · The Lancet Oncology · 2026 · Same journal
• A step forward for precision oncology in thyroid cancer · The Lancet Oncology · 2026 · Same journal
• RCP calls for UK to recognise air pollution as a public health emergency · The Lancet Oncology · 2026 · Same journal
• French MPs vote for sharp cuts in cadmium content in fertilisers · The Lancet Oncology · 2026 · Same journal
• The intermediate-risk gap in AI-based breast cancer stratification · The Lancet Oncology · 2026 · Same journal
• Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial · The Lancet Oncology · 2026 · Same journal
• Gastric cancer with peritoneal metastases: hype or hope for HIPEC? · The Lancet Oncology · 2026 · Same journal
• Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS) · The Lancet Oncology · 2026 · Same journal
• Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study · The Lancet Oncology · 2026 · Same journal